Loading...
XHKG1875
Market cap159mUSD
Dec 20, Last price  
1.60HKD
1D
-1.23%
1Q
-20.00%
IPO
-74.11%
Name

TOT BIOPHARM International Co Ltd

Chart & Performance

D1W1MN
XHKG:1875 chart
P/E
P/S
1.49
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
4.93%
Rev. gr., 5y
81.88%
Revenues
781m
+76.54%
51,608,00039,219,00045,308,00022,491,00076,325,000442,178,000780,629,000
Net income
-38m
L-24.36%
-148,687,000-268,263,000-331,179,000-288,498,000-261,216,000-49,916,000-37,757,000
CFO
56m
-5.84%
-117,388,000-176,832,000-251,329,000-263,116,000-175,137,00059,929,00056,431,000
Earnings
Mar 13, 2025

Profile

TOT BIOPHARM International Company Limited, an investment holding company, engages in the research and development, manufacture, and marketing of anti-tumor drugs in the People's Republic of China. The company's principal drug candidate is TAB008 for the treatment of non-squamous non-small-cell lung cancer metastatic colorectal cancer, glioblastoma multiforme, ovarian cancer, cervical cancer, and hepatocellular carcinoma. It also offers TOZ309 for malignant brain tumor. Further, the company develops TAA013 for HER2+ breast cancer which is under Phase III clinical trial; TAE020 which is under preclinical trial for acute myeloid leukemia; TAB014 for wet age-related macular degeneration and is under Phase II clinical trial. In addition, it develops TAY018 for non-Hodgkin's lymphoma, myelodysplastic syndrome, acute myelogenous leukemia, and solid tumors; TAC020 for various solid tumors; TEP118 for biliary cancer, gallbladder tumors, metastatic cancer, non-small-cell lung cancer (NSCLC), and gastric cancer; TOM312 for cancer and HIV-associated cachexia; TIC318 for epithelial-derived ovarian cancer, small-cell lung cancer, head and neck squamous cell carcinoma, testicular tumors, malignant lymphoma, cervical cancer, bladder cancer, and NSCLC; TVP211 and TID214 for solid tumors; and TIO217 for gastrointestinal tumors. TOT BIOPHARM International Company Limited was incorporated in 2009 and is headquartered in Suzhou, the People's Republic of China.
IPO date
Nov 08, 2019
Employees
431
Domiciled in
CN
Incorporated in
HK

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
780,629
76.54%
442,178
479.34%
76,325
239.36%
Cost of revenue
819,862
489,272
342,735
Unusual Expense (Income)
NOPBT
(39,233)
(47,094)
(266,410)
NOPBT Margin
Operating Taxes
1,000
(2,599)
2,461
Tax Rate
NOPAT
(39,234)
(44,495)
(268,871)
Net income
(37,757)
-24.36%
(49,916)
-80.89%
(261,216)
-9.46%
Dividends
Dividend yield
Proceeds from repurchase of equity
405,788
1,990
BB yield
-26.45%
Debt
Debt current
42,772
77,051
147,654
Long-term debt
304,245
214,374
63,510
Deferred revenue
11,000
Other long-term liabilities
54,050
58,767
53,453
Net debt
(11,347)
(129,525)
56,876
Cash flow
Cash from operating activities
56,431
59,929
(175,137)
CAPEX
(197,281)
(240,123)
(115,313)
Cash from investing activities
(164,105)
(282,764)
(108,393)
Cash from financing activities
38,225
481,240
212,082
FCF
(186,484)
(221,522)
(356,908)
Balance
Cash
358,364
458,047
152,805
Long term investments
(37,097)
1,483
Excess cash
319,333
398,841
150,472
Stockholders' equity
614,214
715,439
335,091
Invested Capital
767,054
673,357
446,637
ROIC
ROCE
EV
Common stock shares outstanding
725,197
639,307
573,360
Price
1.97
-17.92%
2.40
 
Market cap
1,428,638
-6.89%
1,534,337
 
EV
1,417,291
1,406,369
EBITDA
3,795
(9,055)
(232,173)
EV/EBITDA
373.46
Interest
5,175
6,602
2,468
Interest/NOPBT